Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Ligand Pharmaceuticals has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies to...
read more
AMRI announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as "Euticals", a privately-held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active ...
read more
Aphios Corporation announced has been awarded a subcontract for the nanoformulation of a super hydrophobic anticancer drug administered through the Frederick National Laboratory for Cancer Research in Frederick, MD.
read more
Worldwide Clinical Trials will host a free webinar, titled “Are We Moving Toward ‘Siteless’ Clinical Trials? Exploring the Current and Future Potential of Home-Based Studies,” on Thursday, July 14, 2016 at 11 am ET. Leading the discussion will be ...
read more
Recipharm has announced an €18 million investment to expand its blow fill seal (BFS) capacity at its site in Kaysersberg, France
read more
Cambrex Corporation has announced the completion and validation of a $50 million state-of-the-art production and warehousing expansion at its cGMP Charles City, Iowa site. The investment in capacity and capabilities was made in reflection of strong ...
read more
RedHill Biopharma Ltd. has announced the signing of a research collaboration agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), intended to evaluate RedHill’s ...
read more
Mayne Pharma is pleased to announce that it has entered into a binding agreement to acquire a portfolio of U.S. generic products from Teva and Allergan for cash consideration of $652 million.
read more
SGS has invested in a new Genotypic DNA sequencing MicroSeq® Rapid Microbial Identification System from Applied Biosystems at its Chicago, IL facility, located in the suburb of Lincolnshire.
read more
At a meeting held on July 12 for interested residents and other stakeholders, officials of the City of Des Plaines and Vetter were given the opportunity to share initial plans for the proposed purchase and development by Vetter of a 18 acre site, ...
read more
MilliporeSigma is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges, helping accelerate ...
read more
Dr. Reddy’s Laboratories has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules in the United States market, having been ...
read more
Medidata a global provider of cloud-based solutions for clinical research in life sciences, has announced the launch of Medidata Payments. A new component of the Medidata Clinical Cloud®, Medidata Payments enables clinical trial sponsors and contract...
read more
Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is announcing the launch ...
read more
Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VI performance goals letter.
read more